The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
KRAS
LUAD
MYC
PDAC
PITPNC1
Therapy
mTOR
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
20 05 2023
20 05 2023
Historique:
received:
18
10
2022
accepted:
11
05
2023
medline:
22
5
2023
pubmed:
21
5
2023
entrez:
20
5
2023
Statut:
epublish
Résumé
The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipids availability has been appreciated as a mechanism to modulate KRAS oncogenic potential. Thus, phospholipid transporters may play a functional role in KRAS-driven oncogenesis. Here, we identified and systematically studied the phospholipid transporter PITPNC1 and its controlled network in LUAD and PDAC. Genetic modulation of KRAS expression as well as pharmacological inhibition of canonical effectors was completed. PITPNC1 genetic depletion was performed in in vitro and in vivo LUAD and PDAC models. PITPNC1-deficient cells were RNA sequenced, and Gene Ontology and enrichment analyses were applied to the output data. Protein-based biochemical and subcellular localization assays were run to investigate PITPNC1-regulated pathways. A drug repurposing approach was used to predict surrogate PITPNC1 inhibitors that were tested in combination with KRASG12C inhibitors in 2D, 3D, and in vivo models. PITPNC1 was increased in human LUAD and PDAC, and associated with poor patients' survival. PITPNC1 was regulated by KRAS through MEK1/2 and JNK1/2. Functional experiments showed PITPNC1 requirement for cell proliferation, cell cycle progression and tumour growth. Furthermore, PITPNC1 overexpression enhanced lung colonization and liver metastasis. PITPNC1 regulated a transcriptional signature which highly overlapped with that of KRAS, and controlled mTOR localization via enhanced MYC protein stability to prevent autophagy. JAK2 inhibitors were predicted as putative PITPNC1 inhibitors with antiproliferative effect and their combination with KRASG12C inhibitors elicited a substantial anti-tumour effect in LUAD and PDAC. Our data highlight the functional and clinical relevance of PITPNC1 in LUAD and PDAC. Moreover, PITPNC1 constitutes a new mechanism linking KRAS to MYC, and controls a druggable transcriptional network for combinatorial treatments.
Sections du résumé
BACKGROUND
The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipids availability has been appreciated as a mechanism to modulate KRAS oncogenic potential. Thus, phospholipid transporters may play a functional role in KRAS-driven oncogenesis. Here, we identified and systematically studied the phospholipid transporter PITPNC1 and its controlled network in LUAD and PDAC.
METHODS
Genetic modulation of KRAS expression as well as pharmacological inhibition of canonical effectors was completed. PITPNC1 genetic depletion was performed in in vitro and in vivo LUAD and PDAC models. PITPNC1-deficient cells were RNA sequenced, and Gene Ontology and enrichment analyses were applied to the output data. Protein-based biochemical and subcellular localization assays were run to investigate PITPNC1-regulated pathways. A drug repurposing approach was used to predict surrogate PITPNC1 inhibitors that were tested in combination with KRASG12C inhibitors in 2D, 3D, and in vivo models.
RESULTS
PITPNC1 was increased in human LUAD and PDAC, and associated with poor patients' survival. PITPNC1 was regulated by KRAS through MEK1/2 and JNK1/2. Functional experiments showed PITPNC1 requirement for cell proliferation, cell cycle progression and tumour growth. Furthermore, PITPNC1 overexpression enhanced lung colonization and liver metastasis. PITPNC1 regulated a transcriptional signature which highly overlapped with that of KRAS, and controlled mTOR localization via enhanced MYC protein stability to prevent autophagy. JAK2 inhibitors were predicted as putative PITPNC1 inhibitors with antiproliferative effect and their combination with KRASG12C inhibitors elicited a substantial anti-tumour effect in LUAD and PDAC.
CONCLUSIONS
Our data highlight the functional and clinical relevance of PITPNC1 in LUAD and PDAC. Moreover, PITPNC1 constitutes a new mechanism linking KRAS to MYC, and controls a druggable transcriptional network for combinatorial treatments.
Identifiants
pubmed: 37210549
doi: 10.1186/s12943-023-01788-w
pii: 10.1186/s12943-023-01788-w
pmc: PMC10199551
doi:
Substances chimiques
KRAS protein, human
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
PITPNC1 protein, human
0
Membrane Transport Proteins
0
MYC protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nature. 2007 Aug 16;448(7155):807-10
pubmed: 17676035
Ann Transl Med. 2020 Feb;8(4):126
pubmed: 32175419
Leukemia. 2021 Jan;35(1):1-17
pubmed: 32647323
EMBO J. 2010 Mar 17;29(6):1091-104
pubmed: 20150892
Science. 2015 Aug 21;349(6250):873-6
pubmed: 26293964
J Biol Chem. 2010 Jan 1;285(1):80-94
pubmed: 19864431
Essays Biochem. 2017 Dec 12;61(6):565-584
pubmed: 29233869
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
Front Cell Dev Biol. 2021 Jul 01;9:655731
pubmed: 34277603
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Med. 2008 Aug;14(8):822-7
pubmed: 18641660
Cell Discov. 2020 Feb 11;6:6
pubmed: 32047650
Cancer Cell. 2016 Jan 11;29(1):75-89
pubmed: 26725216
Cancer Res. 2015 Jul 15;75(14):2851-62
pubmed: 25977330
Cell. 2014 Jul 3;158(1):185-197
pubmed: 24954535
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
Nat Genet. 2020 Feb;52(2):231-240
pubmed: 31932696
Biochim Biophys Acta. 2015 May;1849(5):506-16
pubmed: 24704206
Science. 2001 Nov 30;294(5548):1942-5
pubmed: 11729323
Curr Top Microbiol Immunol. 2012;362:185-208
pubmed: 23086419
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
Nat Genet. 2001 Sep;29(1):25-33
pubmed: 11528387
Mol Cell. 1999 Feb;3(2):169-79
pubmed: 10078200
Cell Signal. 1991;3(4):321-32
pubmed: 1657098
Nat Commun. 2017 Feb 21;8:14294
pubmed: 28220783
Nature. 1997 May 22;387(6631):422-6
pubmed: 9163430
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Mol Cell. 2020 Jun 18;78(6):1002-1018
pubmed: 32559422
Cancer Discov. 2022 Sep 2;12(9):2198-2219
pubmed: 35771494
J Cancer Metastasis Treat. 2020;6:
pubmed: 33521321
Cancer Cell. 2020 Apr 13;37(4):543-550
pubmed: 32289276
Proc Natl Acad Sci U S A. 2021 Dec 21;118(51):
pubmed: 34903667
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354
pubmed: 29288237
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Curr Opin Genet Dev. 2010 Feb;20(1):87-90
pubmed: 20006486
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683891
Molecules. 2021 Jul 26;26(15):
pubmed: 34361644
J Biol Chem. 2012 Dec 21;287(52):43573-84
pubmed: 23124205
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Cancer Cell. 2016 Mar 14;29(3):339-353
pubmed: 26977884
Sci Rep. 2018 Jun 22;8(1):9511
pubmed: 29934528
J Biol Chem. 2012 Sep 14;287(38):32263-76
pubmed: 22822086
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Res. 2012 Nov 15;72(22):5744-56
pubmed: 22962265
Autophagy. 2007 Nov-Dec;3(6):542-5
pubmed: 17611390
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
Autophagy. 2021 Jan;17(1):1-382
pubmed: 33634751
Cancer Discov. 2022 Apr 1;12(4):913-923
pubmed: 35373279
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Cell Biol. 2007 Jun;9(6):706-12
pubmed: 17486115
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
Br J Cancer. 2003 Jul 21;89(2):232-8
pubmed: 12865907
Cell Rep. 2014 Oct 9;9(1):1-8
pubmed: 25263562
J Hepatol. 2021 Aug;75(2):363-376
pubmed: 33887357
Cancer Cell. 2014 Mar 17;25(3):272-81
pubmed: 24651010
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
J Clin Invest. 2010 Nov;120(11):3940-52
pubmed: 20972333
Clin Cancer Res. 2022 Apr 14;28(8):1640-1650
pubmed: 35091439
Mol Immunol. 2020 Dec;128:287-297
pubmed: 33248399
Cancer Res. 2021 Jul 15;81(14):3849-3861
pubmed: 33903121
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
Nature. 2021 Nov;599(7886):679-683
pubmed: 34759319
J Exp Clin Cancer Res. 2019 Sep 11;38(1):399
pubmed: 31511084
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Cancer Cell. 2018 Nov 12;34(5):807-822.e7
pubmed: 30423298
Theranostics. 2018 Oct 29;8(19):5452-5468
pubmed: 30555557
J Clin Invest. 2020 Apr 1;130(4):1879-1895
pubmed: 31874105
Life Sci Alliance. 2019 Aug 26;2(5):
pubmed: 31451509
Gastroenterology. 2022 Dec;163(6):1593-1612
pubmed: 35948109
PLoS Comput Biol. 2008 Feb 29;4(2):e1000013
pubmed: 18463697
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
J Clin Invest. 2018 Dec 3;128(12):5517-5530
pubmed: 30260324
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94
pubmed: 15342917
Nature. 2018 Feb 1;554(7690):62-68
pubmed: 29364867
Oncogene. 2013 Aug 22;32(34):4028-33
pubmed: 22945650
Curr Opin Lipidol. 2017 Oct;28(5):408-413
pubmed: 28692598
Cancer Res. 2018 Nov 1;78(21):6235-6246
pubmed: 30154150
Cancer Res. 2022 Apr 1;82(7):1234-1250
pubmed: 35149590
Cell. 2016 Mar 24;165(1):153-164
pubmed: 26972053
J Biol Chem. 2011 Jan 7;286(1):567-77
pubmed: 21071439
Int J Cancer. 2019 Dec 15;145(12):3376-3388
pubmed: 31407334
Clin Cancer Res. 2022 Apr 14;28(8):1482-1486
pubmed: 34903582